TRIM33 prevents pulmonary fibrosis by impairing TGF-β1 signaling.

Fiche publication

Date publication

mars 2020


The European respiratory journal


Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen, Dr DEMIDOV Oleg, Dr BELLAYE Pierre-Simon, Pr BONNIAUD Philippe, Dr BELTRAMO Guillaume

Tous les auteurs :
Boutanquoi PM, Burgy O, Beltramo G, Bellaye PS, Dondaine L, Marcion G, Pommerolle L, Vadel A, Spanjaard M, Demidov O, Mailleux A, Crestani B, Kolb M, Garrido C, Goirand F, Bonniaud P


Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterised by myofibroblast proliferation and abnormal extracellular matrix (ECM) accumulation in the lungs. Transforming-growth-factor (TGF)-β1 initiates key profibrotic signaling involving the SMADs pathway and the small heat shock protein αB-crystallin (HSPB5). TRIpartite Motif-containing 33 (TRIM33) has been reported to negatively regulate TGF-β/SMADs signaling but its role in fibrogenesis remains unknown.


Eur. Respir. J.. 2020 Mar 17;: